Insulin Glargine
Проводит Sanofi
Страница компанииAsian Treat to Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label, Parallel-Group, 24-Week Phase IV Study Evaluating the Effectiveness and Safety of Physician Versus Patient-led Initiation and Titration of Insulin Glargine in Type 2 Diabetes Mellitus
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01169818/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 40–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 555 чел. во всех странах исследования.
- Плановая дата окончания (06.2012) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Индекс массы тела20–40 кг/м²
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 27
Критерии включения
- Diagnosed with T2DM duration of T2DM > 2 years
- Insulin naïve
- Continuous treatment with stable doses of 2 OADs (sulphonylureas, biguanides, alpha-glucosidase inhibitors, DPP-IV inhibitors, and glinides) for > three months prior to randomization
- HbA1c levels 7% and 11 %
- Body mass index (BMI) 20 and 40 kg/m2
- Willing and able to perform blood glucose monitoring using a blood glucose meter
Критерии невключения
- Diabetes other than type 2 diabetes (e.g. secondary to pancreatic disorders, drug or chemical agent intake),
- Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for < 1 week),
- Current treatment with thiazolidinediones,
- Current or previous use (within the last 3 months) of GLP-1 receptor agonists or GLP-1 analogues,
- Current or previous (within the last 3 months) use of any treatment for weight lost,
- Active proliferative diabetic retinopathy,
- Patient without any history of eye examination in the past 6 months,
- Treatment with systemic corticosteroids in the 3 months prior to study entry,
- Currently receiving treatment with monoamine oxidase inhibitors,
- Currently receiving treatment with non-selective -blockers,
- Treatment with any investigational product and/or device in the 2 months prior to study entry,
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical trial protocol,
- History of ketoacidosis or hyperosmolar hyperglycemic state,
- History of stroke, myocardial infarction, angina pectoris, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the previous 12 months,
- History of congestive heart failure,
- History of hypoglycemia unawareness,
- Unexplained hypoglycemia in the past 6 months,
- Impaired renal function defined as, but not limited to, serum creatinine 1.5 mg/dL (133 mol/L) males or 1.4 mg/dL (124 mol/L) females or presence of macroproteinuria (>2gr/day),
- Active liver disease (alanine transaminase ALAT greater than two times the upper limit of the reference range, as defined by the local laboratory),
- Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol,
- Had a blood transfusion or severe blood loss within the 3 months before screening, or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia,
- Known hypersensitivity / intolerance to insulin glargine or any of its excipients,
- History of pancreatitis,
- Currently undergoing therapy or planned radiological examinations requiring the administration of contrasting agents for malignancy (other than non-metastatic / early stage basal cell or squamous cell carcinoma),
- Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method),
- Any medical condition that may have an influence on HbA1c rate.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Источник: ClinicalTrials.gov, NCT01169818 · запись обновлена в реестре 8 июля 2013.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 11
- Change (decrease) in mean hemoglobin glycosylated (HbA1c) level — from week 0 (baseline) to week 24 (end of study)
Цель исследования
Primary Objective:
To compare patient-led titration (intervention group) versus physician-led titration (usual standard of care) in optimizing the clinical use of insulin glargine in an Asian population of patients with Type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetic drugs (OADs).
Secondary Objectives:
To determine the difference in glycemic control, safety, quality of life and treatment satisfaction between patient-led titration and usual care.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01169818 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.